Cataract Glaucoma — Cost, Top Hospitals & Success Rates | MyMedicPlus

The coexistence of cataract and glaucoma in the same eye — extremely common in patients above 60 years — presents a clinical management challenge and surgical opportunity. Both conditions increase in prevalence with age: cataracts affect approximately 50% of people above 75, while glaucoma affects approximately 3% of adults above 40 and up to 8% above 70. When both conditions require treatment, the surgeon must decide between staged sequential procedures (cataract surgery first, then glaucoma surgery if needed), simultaneous combined surgery (phacotrabeculectomy), or phacoemulsification combined with minimally invasive glaucoma surgery (MIGS) devices.

Phacoemulsification — ultrasound fragmentation and aspiration of the cataract through a 2–3 mm clear corneal incision — is the standard cataract technique. Glaucoma surgery aims to lower intraocular pressure (IOP) either by creating a new drainage pathway (trabeculectomy, tube shunt) or by reducing aqueous production (cyclodiode laser, ciliary body ablation). Minimally invasive glaucoma surgery (MIGS) devices — iStent, Hydrus Microstent, Kahook Dual Blade goniotomy — can be implanted through the same wound as phacoemulsification, offering modest IOP lowering without the risks of conventional filtration surgery, making them ideal for mild to moderate glaucoma coexisting with cataract.

Treatment planning requires careful assessment of glaucoma severity (disc damage, visual field loss, optic nerve imaging), current IOP on medication, anticipated IOP target, and cataract density and visual impact. Patients with well-controlled glaucoma on few medications can be managed with phacoemulsification plus MIGS; those with advanced glaucoma or uncontrolled IOP may require phacotrabeculectomy or staged filtering surgery.

Primary open-angle glaucoma (POAG) — the most common form of glaucoma, characterised by elevated IOP causing progressive optic nerve damage and visual field loss — coexisting with visually significant posterior subcapsular, nuclear, or cortical cataract is the most frequent clinical scenario. Pseudoexfoliative glaucoma — a secondary glaucoma associated with the deposition of exfoliative material in the angle and on the lens — commonly coexists with a cataract and is particularly amenable to combined phacoemulsification and MIGS, as removal of the cataractous lens and its associated exfoliative material significantly reduces IOP in many cases.

Narrow-angle glaucoma — including primary angle-closure glaucoma (PACG) and plateau iris — may be substantially or completely treated by cataract removal alone, as removing the bulky crystalline lens deepens the anterior chamber and opens the drainage angle. In PACG, phacoemulsification is both therapeutic (treating the causative mechanism of angle closure) and restorative (removing the cataract). Pigmentary glaucoma and neovascular glaucoma coexisting with cataract may require more aggressive glaucoma surgery combined with cataract extraction, depending on IOP control and disease severity.

Patients with visually significant cataract — causing reduction of best corrected visual acuity, glare disability, or difficulty with activities of daily living — and concurrent glaucoma of any severity requiring IOP reduction are candidates for combined treatment. For patients with mild to moderate glaucoma currently on one to two topical medications, phacoemulsification with MIGS device implantation is the preferred combined approach, achieving modest IOP reduction (2–8 mmHg) that may eliminate or reduce the medication burden while simultaneously restoring visual acuity. Patients with moderate to advanced glaucoma requiring more substantial IOP reduction, or those in whom MIGS is insufficient, are candidates for phacotrabeculectomy.

Contraindications to combined surgery include very advanced glaucoma with high IOP requiring urgent maximum IOP lowering (where trabeculectomy alone should precede cataract surgery), active ocular inflammation or infection, significant corneal disease compromising surgical safety, and patients who are not candidates for general or local anaesthesia. Zonular instability from pseudoexfoliation — a risk factor for posterior capsule rupture during phacoemulsification — must be identified pre-operatively and planned for with appropriate intraoperative devices (capsular tension ring, Malyugin ring).

Phacoemulsification with MIGS is the most commonly performed combined procedure for mild to moderate glaucoma. MIGS devices approved for use include iStent inject W (Glaukos) — a micro-bypass stent implanted into Schlemm's canal through the trabecular meshwork; Hydrus Microstent (Alcon) — a larger canal scaffold that bypasses a longer segment of Schlemm's canal; and Kahook Dual Blade goniotomy — excision of the trabecular meshwork to create a direct aqueous outflow path. These devices are implanted through the phacoemulsification wound at the end of cataract surgery using a gonioscope for angle visualisation, adding approximately ten to fifteen minutes to the procedure.

Phacotrabeculectomy combines phacoemulsification with a trabeculectomy (creation of a guarded drainage bleb under the conjunctiva, reinforced with antimetabolites — mitomycin C or 5-fluorouracil — to prevent bleb fibrosis). It achieves more substantial IOP reduction (30–40%) than phacoemulsification alone or MIGS but carries higher complication rates than phacoemulsification alone. Phaco-tube shunt (phacoemulsification combined with Ahmed or Baerveldt glaucoma drainage device implantation) is reserved for eyes with failed trabeculectomy, neovascular glaucoma, or uveitic glaucoma. Laser peripheral iridotomy (LPI) for angle closure followed by phacoemulsification is the sequence for primary angle closure disease. Selective laser trabeculoplasty (SLT) is an effective alternative to drop therapy for open-angle glaucoma and can be combined with phacoemulsification in the same operative episode for angle closure followed by phacoemulsification is the sequence for primary angle closure disease. Post-operative intraocular pressure monitoring at 1 day, 1 week, and 1 month is essential following combined procedures.

Combined cataract and glaucoma surgery avoids the risks of two separate operations under separate anaesthesia, reduces the overall duration and cost of treatment, and provides both visual rehabilitation and IOP control in a single procedure. Phacoemulsification alone produces a modest but clinically meaningful reduction in IOP — typically 2–4 mmHg (10–20% reduction) — in both open-angle and angle-closure glaucoma patients, attributable to relaxation of the trabecular meshwork with lens removal. This effect may suffice to eliminate medication in patients with mild glaucoma, and represents a meaningful additional benefit of cataract surgery in glaucoma patients.

Phacoemulsification plus iStent inject W reduces IOP by an additional 2–4 mmHg versus phacoemulsification alone, with 67–80% of patients achieving target IOP on fewer medications at twelve months in registration trials. Hydrus Microstent demonstrates superior IOP and medication reduction compared to phacoemulsification alone in the HORIZON trial at two years. Phacotrabeculectomy achieves IOP reduction comparable to trabeculectomy alone (30–40% IOP reduction) while simultaneously restoring vision, with approximately 60–70% of patients achieving target IOP medication-free at three years. Successful combined surgery reduces the risk of further glaucoma damage, delays the need for additional glaucoma surgery, and improves patient quality of life.

Phacoemulsification complication rates are low at experienced centres (posterior capsule rupture in 1–2%, dropped nucleus in 0.5%, corneal oedema in 1–2%), but glaucoma eyes have specific risk factors: pseudoexfoliative zonular weakness increases capsule rupture risk; previous trabeculectomy blebs limit conjunctival reserve for future surgery; advanced optic nerve damage increases the risk of IOP spike-related visual loss in the immediate post-operative period. Hypotony maculopathy — transient low IOP after combined surgery causing blurred vision and macular folds — is more common after phacotrabeculectomy than after phacoemulsification alone.

For phacotrabeculectomy, bleb-related complications including bleb failure (fibrosis, approximately 20–30% at five years), bleb leak, blebitis (bleb infection, 1–2% per year), and endophthalmitis (0.2–0.5% lifetime risk) are ongoing concerns requiring long-term surveillance. Encapsulated (Tenon's cyst) bleb formation reduces drainage efficiency and requires needling or revision. For MIGS devices, stent malposition, obstruction, or migration is rare (below 1%) with experienced implants. Post-operative IOP spikes from retained viscoelastic material in the angle are a specific risk in glaucoma eyes and require close monitoring on day one.

After combined phacoemulsification and MIGS, post-operative care follows the standard cataract surgery protocol with additional IOP monitoring. IOP is measured at 4–6 hours post-operatively (or the following morning), then at one week and one month, then regularly thereafter. Topical antibiotic and anti-inflammatory drops are used for four to six weeks. Patients who achieved IOP control on fewer medications should be reassessed at one, three, and six months to determine whether medications can be reduced or stopped. MRI of the visual fields and OCT of the optic nerve are performed at six to twelve months to assess glaucoma stability.

After phacotrabeculectomy, post-operative care is more intensive: bleb massaging to maintain bleb patency, more frequent IOP monitoring, and careful conjunctival hygiene with bleb hygiene instructions. Topical antibiotics are used long-term around the bleb in many protocols. Visual recovery from cataract surgery is typically rapid — most patients achieve excellent distance vision within one to two weeks. Driving is usually permitted within two to seven days of uncomplicated cataract surgery. Long-term annual follow-up with optic nerve and visual field assessment, IOP monitoring, and gonioscopy continues for all glaucoma patients regardless of the surgical technique used.

Combined cataract and glaucoma surgery costs more than cataract surgery alone due to MIGS device costs or the additional surgical time for filtering procedures. In the United States, phacoemulsification alone costs USD 3,000–6,000 per eye; adding an iStent or Hydrus adds USD 1,000–2,000 in device costs. Phacotrabeculectomy costs USD 5,000–12,000 per eye. UK NHS provides standard phacoemulsification for visually significant cataract; MIGS devices are inconsistently funded and may require private payment. In India, cataract surgery at Apollo Eye Hospitals, Aravind Eye Hospital, or LV Prasad Eye Institute costs USD 300–1,500 per eye for standard surgery; MIGS-combined procedures cost USD 1,000–3,000.

India is a world-leading destination for affordable, high-volume, high-quality cataract and glaucoma surgery — Aravind Eye Care System (Madurai, Chennai, Coimbatore, Pondicherry) performs over 400,000 surgeries annually with complication rates equivalent to or better than international benchmarks. Thailand (Rutnin Eye Hospital, Phyathai) charges USD 2,000–5,000 for combined procedures; Turkey USD 1,500–4,000. The combination of high volume, experienced surgeons, and low cost makes India particularly attractive for international cataract-glaucoma patients.

For patients with cataract alone without significant glaucoma, standard phacoemulsification cataract surgery is appropriate without any glaucoma procedure. For patients with glaucoma only, without visually significant cataract, topical IOP-lowering medications (prostaglandin analogues, beta-blockers, carbonic anhydrase inhibitors, alpha-2 agonists), selective laser trabeculoplasty (SLT), or conventional trabeculectomy/tube shunt surgery address glaucoma without the cataract component. Selective laser trabeculoplasty — a non-incisional outpatient laser treatment reducing IOP by 20–30% in open-angle glaucoma — can defer or reduce the need for drops and surgery in early to moderate glaucoma. For angle-closure disease, laser peripheral iridotomy (LPI) prevents acute angle-closure attacks and may control IOP in early angle-closure without requiring immediate cataract surgery.